Abstract

Osteoarthritis (OA), as an “undead cancer”, causes a serious burden for both individuals and society. In this study, a glycosaminoglycan-based injectable hydrogel was prepared with hyaluronic acid (HA), chondroitin sulfate E disaccharide (ΔUA-diSE) and thermosensitive Pluronic F127 (PF127) to provide a new strategy for OA alleviation. Both in vitro and in vivo biological evaluations were introduced to investigate the slow-release capacity, related mechanisms, and effectiveness of PF-HA-diSE on OA. The results demonstrated that PF-HA-diSE could alleviate OA effectively by regulating the complement system, especially the formation of C5b-9, and its downstream signals. Interestingly, we also found that PF127 was not only a drug carrier, but may have the potential on inhibiting C5b-9 formation. Altogether, these findings provided a more effective local drug delivery system for glycosaminoglycans in better treatment of OA and related diseases.